



US00D457246S

(12) **United States Design Patent**
Mazel et al.

(10) **Patent No.:** **US D457,246 S**

(45) **Date of Patent:** **** May 14, 2002**

(54) **PHARMACEUTICAL KIT**

(75) Inventors: **Sidney Mazel**, Basking Ridge, NJ (US);
James M. Mundt, Warrington, PA (US)

(73) Assignee: **Merck & Co., Inc.**, Rahway, NJ (US)

(**) Term: **14 Years**

(21) Appl. No.: **29/115,771**

(22) Filed: **Dec. 20, 1999**

(51) **LOC (7) Cl.** **24-02**

(52) **U.S. Cl.** **D24/223**

(58) **Field of Search** D24/225, 226,
D24/223; D9/345, 340; D20/40; 206/532,
534.1, 534.2, 531; D3/203

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,504,788 A 4/1970 Gray
3,527,190 A 9/1970 Huck

(List continued on next page.)

FOREIGN PATENT DOCUMENTS

CA 866616 3/1971
EP 0 511 726 A2 11/1992
FR 2635507 2/1990
GB 1580583 12/1980
GB 2256853 A 12/1992
WO WO 97/03896 2/1997
WO WO 98/00351 1/1998
WO WO 98/22072 5/1998
WO WO 99/04773 2/1999
WO WO 99/51214 10/1999

OTHER PUBLICATIONS

Greenberg, Clin. Therap., vol. 6 (1984), "Overview of patient compliance with medication dosing: A literature Review", pp. 592-599.

Schnitzer et al., Aging Clin. Exp. Res., vol. 12 (2000), pp. 1-12, "Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis".

Adami et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999, "Rationale for once weekly dosing regimens with alendronate for the treatment and prevention of osteoporosis", p. 48.

(List continued on next page.)

Primary Examiner—Ian Simmons

(74) *Attorney, Agent, or Firm*—Anthony D. Sabatelli;
Melvin Winokur


(57) **CLAIM**

The ornamental design for a pharmaceutical kit, as shown and described.

DESCRIPTION

FIG. 1 is an exploded perspective view, on a reduced scale, of a pharmaceutical kit showing our new design in the fully unfolded position with an uninserted insert card; FIG. 2 is a full scale front plan view thereof; FIG. 3 is a full scale end elevational view thereof; FIG. 4 is a full scale rear plan view thereof; FIG. 5 is a full scale right end elevational view thereof; FIG. 6 is a full scale left end elevational view thereof; FIG. 7 is a full scale front plan view of the insert card of the pharmaceutical kit shown in FIG. 1; FIG. 8 is a full scale rear plan view of the insert card of the pharmaceutical kit shown in FIG. 1; FIG. 9 is a full scale side elevational view of the insert card of the pharmaceutical kit shown in FIG. 1; FIG. 10 is a full scale end elevational view of the insert card of the pharmaceutical kit shown in FIG. 1; FIG. 11 is a full scale perspective view of the pharmaceutical kit shown in FIG. 1 in the fully folded position; and, FIG. 12 is an exploded perspective view, on a reduced scale, in the fully unfolded position with a partially inserted insert card.

1 Claim, 7 Drawing Sheets



US D457,246 S

Page 2

U.S. PATENT DOCUMENTS

3,677,397 A 7/1972 Beckham
4,199,569 A 4/1980 Chabala et al.
4,243,144 A 1/1981 Margulies
4,295,567 A 10/1981 Knudsen
4,340,141 A 7/1982 Du Pont
4,425,339 A 1/1984 Pitchford
4,506,789 A * 3/1985 Dlugosz 206/534.1
4,534,468 A 8/1985 Nuckols et al.
4,573,580 A 3/1986 Messer
4,736,849 A 4/1988 Leonard et al.
4,761,406 A 8/1988 Flora et al.
4,848,582 A * 7/1989 Levasseur et al. 206/534.2
4,889,237 A 12/1989 Brandon
4,889,238 A 12/1989 Batchelor
4,974,729 A * 12/1990 Steinnagel 206/534.1
5,050,739 A * 9/1991 Hannan et al 206/534
5,242,055 A 9/1993 Pora
5,265,728 A 11/1993 Allendorf et al.

5,339,960 A 8/1994 Price
5,393,100 A 2/1995 Coc
RE35,445 E 2/1997 Pora
5,755,462 A 5/1998 Lupi
5,833,072 A 11/1998 Lambelet, Jr.
5,915,559 A 6/1999 Hulick et al.
5,927,500 A 7/1999 Godfrey et al.
5,994,329 A 11/1999 Daifotis et al.
6,024,222 A 2/2000 Friberg et al.

OTHER PUBLICATIONS

Bone III et al., 6th Int'l Symposium on Clinical Disorders of Bone and Mineral Metabolism, Nov. 1999, "Alendronate 70 mg once weekly is therapeutically equivalent to alendronate 10 mg daily", p. 55.

Copy of dispenser package and insert for Heartgard 30® (ivermectin) chewables, Merck & Co., Inc., Oct. 1988.

* cited by examiner





FIG. 1






FIG. 4



FIG. 5



FIG. 6




FIG. 8




FIG. 7

FIG. 9



FIG. 10




FIG.11




FIG. 12